Please ensure Javascript is enabled for purposes of website accessibility

Why Ampio Pharmaceuticals Rose as Much as 15% Today

By Maxx Chatsko - Dec 28, 2017 at 12:31PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The small-cap biopharma stock has exploded at the end of 2017.

What happened

Shares of Ampio Pharmaceuticals (AMPE -4.76%) gained 15% today because, well, that's become the norm lately. The stock is up 85% in the last five trading days and has gained 112% in the last month alone. You may be thinking the company announced a new cryptocurrency, but there's a simpler explanation.

On Dec. 14, Ampio Pharmaceuticals announced that its lead drug candidate, Ampion, met both primary and secondary endpoints in a phase 3 trial for severe osteoarthritis of the knee. Mr. Market surely wasn't expecting that outcome, casting the company aside as just another penny stock. The company had a market cap of just $25 million in mid-August and was valued at roughly $100 million entering this month. 

Today's move is simply an extension of the momentum from that announcement as Mr. Market reconsiders the company's market cap. As of 11:06 a.m. EST Thursday, the stock had settled to an 11.6% gain.

A cartoon of a rocket ship soaring over increasingly taller columns of coins.

Image source: Getty Images.

So what

The phase 3 results appeared to be pretty rosy for Ampion. The drug candidate met its primary endpoint with 71% of treated patients reporting a response based on a rating scale used by physicians. A meaningful treatment for severe osteoarthritis of the knee needs only to achieve 30% in the eyes of doctors. The drug was also well-tolerated, with no reports of treatment-emergent adverse events.

AMPE Market Cap Chart

AMPE Market Cap data by YCharts

The next step involves meeting with the U.S. Food and Drug Administration and submitting a Biologics License Application for Ampion. In the best-case scenario in which the drug is approved, investors will likely have to wait a few more quarters before the product hits the market.

Now what

Investors may want to think twice about jumping on this rocket ship. One reason: It would be very wise for management to take advantage of its good fortune -- and a rising stock price -- to raise funds through a stock offering in the near future. Ampio Pharmaceuticals boasted just $1.8 million in cash at the end of the third quarter of 2017. That's not going to cut it for its multiple ongoing clinical trials and, if Ampion is approved, launching its first product.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ampio Pharmaceuticals, Inc. Stock Quote
Ampio Pharmaceuticals, Inc.
AMPE
$0.16 (-4.76%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
311%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.